United States, June 24 -- GE HealthCare's commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana.As cardiovascular disease (CVD) continues to rise globally, the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies - including positron emission tomography-computed tomography (PET/CT) and single-photon emission computed tomography-computed tomography (SPECT/CT) - and radiopharmaceuticals - namely its Flyrcado (TM) (flurpiridaz F 18) injection - play a crucial role in cardiac care by providing detailed ...